

# Line Schmidt Tarpgaard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1679500/publications.pdf>

Version: 2024-02-01

18  
papers

351  
citations

1163117

8  
h-index

1058476

14  
g-index

18  
all docs

18  
docs citations

18  
times ranked

824  
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. <i>Molecular Oncology</i> , 2015, 9, 1169-1185.	4.6	91
2	High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. <i>Molecular Oncology</i> , 2013, 7, 637-646.	4.6	77
3	Quality of life in patients with cancer during the COVID-19 pandemic – a Danish cross-sectional study (COPICADS). <i>Acta Oncologica</i> , 2021, 60, 4-12.	1.8	39
4	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430.	2.5	39
5	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. <i>BMC Cancer</i> , 2016, 16, 91.	2.6	26
6	Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , 2014, 9, e87746.	2.5	18
7	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 48.	2.6	17
8	The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer. <i>BMC Genomics</i> , 2015, 16, 404.	2.8	13
9	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. <i>International Journal of Cancer</i> , 2015, 137, 2470-2477.	5.1	8
10	Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer. <i>Annals of Oncology</i> , 2021, 32, 805-806.	1.2	7
11	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 59441-59457.	1.8	7
12	New use for old drugs: Epirubicin in colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 954-956.	1.8	5
13	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3572-3572.	1.6	2
14	Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC). <i>Pleura and Peritoneum</i> , 2022, 7, 143-148.	1.2	2
15	Plasma concentrations of YKL-40 in chemo-naïve patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3548-3548.	1.6	0
16	Plasma levels of TIMP-1 in chemo-naïve patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 392-392.	1.6	0
17	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14710-e14710.	1.6	0
18	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3590-3590.	1.6	0